GlaxoSmithKline's Profit Surge: A Testament to Resilience

GlaxoSmithKline Pharmaceuticals reported a significant increase in net profit to Rs 229 crore for the third quarter ending December 31, 2024. This growth reflects their commitment to innovative healthcare and a strong market presence. Revenue rose to Rs 949 crore with major gains in both general medicines and vaccines.

GlaxoSmithKline Pharmaceuticals experienced a substantial rise in net profit, reaching Rs 229 crore in the third quarter ending December 31, 2024. This marks an over five-fold increase compared to the Rs 45 crore recorded in the corresponding quarter of the previous fiscal year.

The company's revenue from operations also saw an upswing, climbing to Rs 949 crore from Rs 805 crore in the same period last year. GlaxoSmithKline Pharmaceuticals attributes this success to their ongoing commitment to providing innovative healthcare solutions across India.

With a focus on strengthening core brands and accelerating digital transformation, the company enhanced its market presence. Key products like Augmentin, Ceftum, and T-bact gained market share, while GSK maintained leadership in the self-pay private paediatric vaccines market.

(With inputs from agencies.)